Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection

Expert Opinion on Biological Therapy

Volumn 3, Issue 1, 2003, Pages 85-95

  Dedrick, Russell L ^a   Bodary, Sarah ^b   Garovoy, Marvin R ^a  

^a XOMA Corporation   (United States)

^b GENENTECH INC   (United States)

Author keywords

Adhesion blockade; Autoimmunity; Inflammation; Leukocyte trafficking; Transplantation

Indexed keywords

ALICAFORSEN; BETA1 INTEGRIN; CDP 850; CELL ADHESION MOLECULE; EFALIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOLOGIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; ODULIMOMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AUTOIMMUNE DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENTERITIS; EXTRAVASATION; FEVER; FLU LIKE SYNDROME; GRAFT REJECTION; HEADACHE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; MOUSE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; PSORIASIS; RAT; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VOMITING;

ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; CELL ADHESION MOLECULES; DRUG DELIVERY SYSTEMS; GRAFT REJECTION; HUMANS;

ANIMALIA;

EID: 0037321262     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.1.85     Document Type: Review

References (104)

1. SPRINGER TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301-314. An excellent review of leukocyte trafficking components.
2. BUTCHER EC, PICKER LJ: Lymphocyte homing and homeostasis. Science (1996) 272:60-66. An excellent review of leukocyte homing regulation.
3. LAWRENCE MB, SPRINGER TA: Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell (1991) 65:859-873.
4. KANSAS GS: Selectins and their ligands: current concepts and controversies. Blood (1996) 88:3259-3287.
5. FUHLBRIGGE RC, KIEFFER JD, ARMERDING D, KUPPER TS: Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature (1997) 389:978-981.
6. TIETZ W, ALLEMAND Y, BORGES E et al.: CD4+ T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J. Immunol. (1998) 161:963-970.
7. NELSON PJ, KRENSKY AM: Chemokines, chemokine receptors, and allograft rejection. Immunity (2001) 14:377-386.
8. DUSTIN ML, ROTHLEIN R, BAHN AK, DINARELLO CA, SPRINGER TA: Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. (1986) 137:245-254.
9. OSBORN L, HESSION C, TIZARD R et al.: Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell (1989) 59:1203-1211.
10. CONSTANTIN G, MAJEED M, GIAGULLI C et al.: Chemokines trigger immediate β2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity (2000) 13:759-769.
11. MAMPASO F, SANCHEZ-MADRID F, MARCEN R et al.: Expression of adhesion molecules in allograft renal dysfunction a distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation (1993) 56:687-691.
12. TAKADA M, NADEAU KC, SHAW GD, MARQUETTE KA, TILNEY NL: The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney, inhibition by a soluble P-selectin ligand. J. Clin. Invest. (1997) 99:2682-2690.
13. KOCH AE, BURROWS JC, HAINES GK, CARLOS TM, HARLAN JM, LEIBOVICH J: Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissue. Lab. Invest. (1991) 64:343-320.
14. DE BOER OJ, WAKELKAMP IMM J, PALS ST, CLAESSEN N, BOS JD, DAS PK: Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch. Dermatol. Res. (1994) 286:304-311.
15. CANNELLA B, RAINE CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. (1995) 37:424-435.
16. AUSTRUP F, VESTWEBER D, BORGES E et al.: P- and E-selectin mediate recruitment of T-helper-1 but notT-helper-2 cells into inflamed tissues. Nature (1997) 385:81-83. T cell trafficking to inflamed tissue is controlled in part by selectin expression.
17. ISSEKUTZ AC, MU JY, MELROSE J, BERG EL: E-selectin, but not P-selectin, is required for development of adjuvant-induced arthritis in the rat. Arthritis Rheum. (2001) 44:1428-1437.
18. ENGELHARDT B, VESTWEBER D, HALLMANN R, SCHULTZ M: E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood (1997) 90:4459-4472.
19. PODOLSKY DK, LOBB R, KING N et al.: Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J. Clin. Invest. (1993) 92:372-380.
20. BHUSHAN M, BLEIKER TO, BALLSDON AE et al.: Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. (2002) 146:824-831.
21. BERLIN C, BARGATZE RF, CAMPBELL JJ et al.: α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell (1995) 80:413-422.
22. FRENETTE PS, MAYADAS TN, RAYBURN H, HYNES RO, WAGNER DD: Susceptibility to infection and altered hematopoesis in mice deficient in both P- and E-selectins. Cell (1996) 84:563-574.
23. ETZIONI A, FRYDMAN M, POLLACK S et al.: Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency, N. Engl. J. Med. (1992) 327:1789-1792.
24. WEYRICH AS, MA X-L, LEFER DJ, ALBERTINE KH, LEFER AM: In vivo neutralization of P-selectin protects feline heart and endothelium. in myocardial ischemia and reperfusion injury. J. Clin. Invest. (1993) 91:2620-2629.
25. KUSAKA M, PRATSCHKE J, WILHELM MJ et al.: Activation of inflammatory mediators in rat renal isografts by donor brain death. Transplantation (2000) 69:405-410.
26. WINN RK, LIGGITT D, VEDDER NB, PAULSON JC, HARLAN JM: Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J. Clin. Invest. (1993) 92:2042-2047.
27. LEVINE AJ, PARKES K, ROONEY SJ, BONSER RS: The effect of adhesion molecule blockade on pulmonary reperfusion injury. Ann. Thorac. Surg. (2002) 73:1101-1106.
28. PRATSCHKE J, KOLFA G, WILHELM MJ et al.: Improvements in early behavior of rat kidney allografts after treatment of the brain-dead donor. Ann. Surg. (2001) 234:732-740. Immune rejection in the host can be modified by inhibiting selectin-mediated neutrophil trafficking in the donor.
29. SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346:425-434.
30. LUSCINSKAS FW, BROCK AF, ARNAOUT MA, GIMBRONE MA: Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CD11/CD18)-dependent mechanisms contribute to polmorphonuctear lukocyte adhesion to cytokine-activated human vascular endothelium. J. Immunol. (1989) 142:2257-2263.
31. VEDDER NB, WINN RK, RICE CL, CHI EY, ARFORS K-E, HARLAN JM: Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear. Proc. Natl. Acad. Sci. USA (1990) 87:2643-2646.
32. SHARAR SR, WINN RK, MURRY CE, HARLAN JM, RICE CL: A CD18 monoclonal antibody increases the incidence and severity of subcutaneous abscess formation after high-dose Staphylococcus aureus injection in rabbits. Surgery (1991) 110:213-220.
33. SCHARFFETTER-KOCHANEK K, LU H, NORMAN K et al.: Spontaneous skin ulceration and defective T cell function in CD18 null mice. J. Exp. Med. (1998) 188:119-131.
34. ANDERSON DC, SPRINGER TA: Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Ann. Rev. Med. (1987) 38:175-194.
35. OSTERMANN G, WEBER KSC, ZERNECKE A, SCHRÖDER A, WEBER C: JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. (2002) 3:151-158.
36. GRAKOUI A, BROMLEY SK, SUMEN C et al.: The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221-227.
37. MONKS CR, FREIBERG BA, KUPFER H, SCIAKY N, KUPFER A: Three-dimensional segregation of supramolecular activation clusters in T cells. Nature (1998) 395:82-86.
38. DOUGHERTY GJ, HOGG N: The role of monocyte lymphocyte-associated antigen 1 (LFA-1) in accessory cell function. Eur. J. Immunol. (1987) 17:943-947.
39. DAVIGNON D, MARTZ E, REYNOLDS T, KURZINGER K, SPRINGER TA: Monoclonal antibody to a novel lymphocyte function-associated antigen (LFA-1): mechanism of blockade of T lymphocyte-mediated killing and effects on other T and B lymphocyte functions. J. Immunol. (1981) 127:590-595.
40. DEDRICK RL, WALICKE P, GAROVOY M: Anti-adhesion antibodies: efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol. (2002) 9:181-186.
41. KAKIMOTO K, NAKAMURA T, ISHII K et al.: The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell. Immunol. (1992) 142:326-337.
42. CONNOLLY MK, KITCHENS EA, CHAN B, JARDIEU P, WOFSY D: Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin. Immunol. Immunpathol. (1994) 72:198-203.
43. NAKAKURA EK, MCCABE SM, ZHENG B et al.: Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion. Transplant. Proc. (1993) 55:412-417.
44. ISOBE M, YAGITA H, OKUMURA K, IHARA A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science (1992) 255:1125-1127.
45. NAKAKURA EK, SHORTHOUSE RA, ZHENG B, MCCABE SM, JARDIEU PM, MORRIS RE: Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation (1996) 62:547-552.
46. BEHREND M: Immune-adhesion molecules in the prevention of allograft rejection and reperfusion injury. Ex. Opin. Investig. Drugs (2000) 9:789-805. A recent review of anti-adhesion therapies.
47. STOPPA AM, MARANINCHI D, BLAISE D et al.: Anti-LFA-1 monoclonal antibody (25.3) for treatment of steroid-resistant grade III-IV acute graft-versus-host disease. Transplant. Int. (1991) 4:3-7.
48. FISCHER A, FRIEDRICH W, FASTH A et al.: Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European group for immunodeficiency/European group for bone marrow transplantation report. Blood (1991) 77:249-256.
49. CAVAZZANA-CALVO MS, BORDIGONI P, MICHEL G: A Phase II trail of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Br. J. Haematol. (1996) 93:131-138.
50. LE MAUFF B, HOURMANT M, ROUGIER J-P et al.: Effect of anti-LFA-1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation (1991) 52:291-296.
51. HOURMANT M, BEDROSSIAN J, DURAND D et al.: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation (1996) 62:1565-1570.
52. GABER AO: Prospective study of anti-CD11a antibody in prevention of delayed graft function (DGF) in recipients of highrisk renal cadaver grafts. Transplant 2001 Joint Meeting (2001) May 2001.
53. PEREZ N, LE DEIST F, CHATENOUD L, CHANTELOUP N, GRISCELLI C, FISCHER A: In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. Bone Marrow Transplant. (1989) 4:379-384.
54. WERTHER WA, GONZALEZ TN, O'CONNOR SJ et al.: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. (1996) 157:4986-4995.
55. BOS JD, DE RIE MA: The pathogenesis of psoriasis: immunological facts and speculations. Immunol. Today (1999) 20:40-46.
56. BAUER RJ, DEDRICK RL, WHITE ML, MURRAY MJ, GAROVOY MR: Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokin. Biopharm. (1999) 27:397-420.
57. GOTTLIEB A, KRUEGER JG, BRIGHT R et al.: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. (2000) 42:428-435. An overview of the clinical effects of inhibiting CD11a function with efalizumab.
58. GOTTLIEB AB, KRUEGER JG, WITTKOWSKI K, DEDRICK RL, WALICKE PA, GAROVOY MR: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch. Dermatol. (2002) 138:591-600.
59. PAPP K, BISSONNETTE R, KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J. Am. Acad. Dermatol. (2001) 45:665-674. Clinical results with efalizumab in a placebo-controlled psoriasis study.
60. LEBWOHL M, MILLER JL, GOLDMAN M et al.: Continued treatment with efalizumab (anti-CD11a) improves outcome in patients with moderate to severe plaque psoriasis. American Academy of Dermatology Annual Meeting 2002 (2002):216.
61. VINCENTI F, MENDEZ R, RAJAGOPAPAN PR et al.: A Phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. Transplant 2001 joint Meeting (2001) May 2001.
62. CAMACHO SA, HEATH WR, CARBONE FR et al.: A key role for ICAM-1 in generating effector cells mediating inflammatory responses. Nat. Immunol. (2001) 2:523-529.
63. CHIRATHAWORN C, KOHLMEIER JE, TIBBETTS SA, RUMSEY LA, CHAN MA, BENEDICT SH: Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J. Immunol. (2002) 168:5530-5537.
64. IIGO Y, TAKASHI T, TAMATANI T et al.: ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J. Immunol. (1991) 147:4167-4171.
65. COSIMI AB, CONTI D, DELMONICO FL et al.: In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J. Immunol. (1990) 144:4604-4612.
66. HAUG CE, COLVIN RB, DELMONICO FL et al.: A Phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation (1993) 55:766-773.
67. KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37:992-999.
68. VUORTE J, LINDSBERG PJ, KASTE M et al.: Anti-ICAM-1 monoclonal antibody R6.5 (enlimomab) promotes activation of neutrophils in whole blood. J. Immunol. (1999) 162:2353-2357.
69. BENNETT CF, CONDON TP, GRIMM S, CHAN H, CHIANG M-Y: Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J. Immunol. (1994) 152:3530-3540.
70. STEPKOWSKI SM, TU Y, CONDON TP, BENNETT CF: Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. (1994) 153:5336-5346.
71. YACYSHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al.: A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology (1998) 114:1133-1142.
72. MAKSYMOWYCH WP, BLACKBURN WD JR, TAMI JA, SHANAHAN WR: A randomized, placebo controlled trial of an antisense oligonucleotide to intracellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. J. Rheumatol. (2001) 29:447-453.
73. SHEEHAN JP, LAN H-C: Phosphorothioate oligonucleotides inhibit intrinsic tenase complex. Blood (1998) 92:1617-1625.
74. ISIS PHARMACEUTICALS INC.: Isis announces disappointing results form ISIS 2302 clinical trial in Crohn's disease. Press Release (1999) December 15, 1999.
75. ELICES MJ, OSBORN L, TAKADA Y et al.: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell (1990) 60:577-584.
76. ELICES MJ, TSAI V, STRAHL D et al.: Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J. Clin. Invest. (1994) 93:405-416.
77. COITO AJ, BROWN LF, PETERS JH, KUPIEC-WEGLINSKI JW: Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am. J. Pathol. (1997) 150:1757.
78. 4-integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. (1994) 152:3282-3293.
79. BARON JL, MADRI JA, RUDDLE NH, HASHIM G, JANEWAY CA JR.: Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. (1993) 177:57-68.
80. 1 integrin. Nature (1992) 356:63-66.
81. KENT SJ, KARLIK SJ, CANNON C et al.: A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. (1995) 58:1-10.
82. VAN DER LAAN LJW, VAN DER GOES A, WAUBEN MHM et al.: Beneficial effect of modified peptide inhibitor of α4 integrins on experimental allergic encephalomyelitis in Lewis rats. J. Neurosci. Res. (2002) 67:191-199.
83. ISSEKUTZ TB, ISSEKUTZ AC: T lymphocyte migration to arthritic joints and dermal inflammation in the rat: differing migration patterns and the involvement of VLA-4. Clin. Immunol. Immunopathol. (1991) 61:436-447.
84. ISSEKUTZ TB: Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody: a likely role for VLA-4 in vivo. J. Immunol. (1991) 147:4178-4184.
85. 2 integrin dependent. J. Immunol. (2001) 166:596-601.
86. ISOBE M, SUZUKI J-I, YAGITA H et al.: Immunosuppression to cardiac allografts and soluble antigens by anti-vascular cellular adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies. J. Immunol. (1994) 153:5810-5818.
87. COITO AJ, KOROM S, GRASER E, VOLK H-D, VAN DE WATER L, KUPIEC-WEGLINSKI JW: Blockade of very late antigen-4 integrin binding to fibronectin in allograft recipients: I. treatment with connecting segment-1 peptides prevents acute rejection by suppressing intragraft mononuclear cell accumulation, endothelial activation, and cytokine expression. Transplantation (1998) 65:699-706.
88. STEGALL MD, DEAN PG, NINOVA D et al.: α4 integrin in islet allograft rejection. Transplantation (2001) 71:1549-1555.
89. HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ et al.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut homing integrin α4β7. Gastroenterology (1996) 111:1373-1380.
90. TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology (1999) 53:466-472.
91. GORDON FH, LAI CWY, HAMILTON MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology (2001) 121:268-274.
92. GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment. Pharmacol. Ther. (2002) 16:699-705.
93. ELAN CORPORATION: Elan and Biogen begin Phase III clinical trials of Antegren (natalizumab) in multiple sclerosis and Crohn's disease. Press Release (2001) December 18, 2001.
94. FEAGAN BG, MCDONALD J, GREENBERF G et al.: An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis (UC). Gastroenterology (2000) 118A874.
95. BEVILACQUA MP: Endothelial-leukocyte adhesion molecules. Ann. Rev. Immunol. (1993) 11:767-804.
96. VAN SEVENTER GA, NEWMAN W, SHIMIZU Y et al.: Analysis of T cell stimulation by superanngen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1 but not ELAM-1. J. Exp. Med. (1991) 174:901-913.
97. LUKAS NW, STRIETER RW, EVANOFF HL, BURDICK MD, KUNKEL SL: VCAM-1 influences lymphocyte proliferation and cytokine production during mixed lymphocyte responses. (1994) 154:88-98.
98. CARTER RA, CAMPBELL IK, O'DONNELL K, WICKS IP: Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Clin. Exp. Immunol. (2002) 128:44-51.
99. SORIANO A, SALAS A, SALAS A et al.: VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. (2000) 80:1541-1551. Inflammatory bowel disease is mediated by leukocyte trafficking to sites of inflammation rather than to the gut in general.
100. GADEK TR, BURDICK DJ, MCDOWELL RS et al.: Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science (2002) 295:1086-1089.
101. LIN K-C, CASTRO A: Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr. Opin. Chem. Biol. (1998) 2:453-457.
102. WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
103. WOSKA JR JR., SHIH D-T, TAQUETI VR, HOGG N, KELLY TA, KISHIMOTO TK: A small-molecule antagonist of LFA-1 blocks a conformational change important for LFA-1 function. J. Leukoc. Biol. (2001) 70:329-334.
104. YUSUF-MAKAGIANSAR H, ANDERSON ME, YAKOVLEVA TV, MURRAY JS, SIAHAAN TJ: Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. (2002) 22:146-167.